Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients
August 05 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Collaborates with Right to Try Foundation on Novel
Means of Protecting Patients While
Hyper-accelerating Drug
Development
Company Plans to Advance its Phase
I Cancer Immunotherapy StemVacs™ to US Patients
OCEANSIDE, CA --
August 5, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) together with The
Right to Try Foundation announced filing of a patent covering its
proprietary method of implementing S.204, the Trickett Wendler,
Frank Mongiello,
Jordan McLinn and Matthew Bellina
Right to
Try Act in a manner which provides a novel means of safeguarding
patients while allowing rapid access to experimental
medications.
The patent
application is based on the current Standard Operating Procedures
of the Right to Try Foundation, which call for a physical or
virtual independent Institutional Review Board assessment of each
patient considered for an experimental medication.
"The fact that
publicly this new pathway of providing hope to patients with no
hope has only been used two times [1]
since the law was passed
is appalling"
said Famela Ramos,
President and Founder of the Right to Try Foundation. "Why are
American patients with terminal illnesses travelling to hospitals
outside the USA when so many experimental treatments are available
here? By establishing an independent means of ensuring patients are
protected, we believe that we solve the issue that many opponents
of the law raise, which is that patients will be victims of
predatory companies."
The Right to Try
Foundation seeks to accelerate medical progress by establishing
means by which drugs that are demonstrated safe can be used for
different diseases or in combinations with other drugs based on the
ideas of the doctors and not the Pharmaceutical
Companies.
Therapeutic Solutions
International has a filed Investigational New Drug (IND)
application for StemVacs™ a novel Cell Based Cancer
Immunotherapy [2]
that
specifically trains the immune system to kill cancer stem
cells.
"Immunotherapy is the
greatest advancement in the area of clinical oncology," said James
Veltmeyer, MD, Chief
Medical
Officer of Therapeutic
Solutions International. "To our knowledge, StemVacs™ is the only
clinical stage immunotherapeutic that kills cancer stem cells.
This, combined with the safety and signals of efficacy obtained
from the current Phase 1 clinical trial, support us to expand the
use of StemVacs™ under President Trump's recently passed Right to
Try Law. I applaud Timothy Dixon and Famela Ramos for this
joint collaboration leading to a new pathway to take drugs into the
clinic with an added level of safety."
"We have highly
benefitted from working with the Right to Try Foundation in terms
of establishing necessary procedures and systems to not only
utilize this new law but to collect data in a Good Clinical
Practices compliant manner, said Timothy
Dixon,
President and CEO of Therapeutics Solutions International.
"Our Phase I safety
data motivates us to
continue clinical development
of StemVacs™, of which part of the development pathway
absolutely
includes
providing patients access to it now under the Right to Try Law and
we are very excited to continue our work with Right To Try
Foundation."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] https://www.raps.org/news-and-articles/news-articles/2019/5/right-to-try-one-year-later-limited-patient-invol
[2] http://www.stemvacs.com
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024